Results 121 to 130 of about 6,845,583 (296)

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

open access: yesMolecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla   +9 more
wiley   +1 more source

Bell–Clauser–Horne–Shimony–Holt Behavior Under Quantum Loss and Decoherence

open access: yesCryptography
We present a detailed analysis of the effect of quantum loss and decoherence in the Bell-CHSH scenario. Adopting a device-independent approach, we study the change in the bipartite conditional probability distribution, i.e., the behavior of the realized ...
Ottó Hanyecz   +3 more
doaj   +1 more source

Participants de MAPS 12

open access: yes, 2019
Les participants de MAPS 12 sont des participants du consortium LittoSIM et des membres du noyau de MAPS. Marion Amalric Frédéric Amblard Nicolas Becu Élise Beck Xavier Bertin Nathalie Corson Benoit Gaudou Ahmed Laatabi Nicolas Marilleau Cecilia Pignon ...
Réseau MAPS
core  

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

open access: yesMolecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis   +3 more
wiley   +1 more source

MAPS 10, c'est fini!

open access: yes, 2017
MAPS 10, c'est déjà fini?! Que de bons souvenirs! Vous trouverez prochainement les productions des brillants groupes-projets de MAPS 10 sur ce site. En attendant, vous pouvez retrouvez quelques photos souvenirs sur ce lien et les présentations de vos ...
Réseau MAPS
core  

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

open access: yesMolecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober   +16 more
wiley   +1 more source

A new proof for monotonicity of sandwiched Renyi relative entropy

open access: yes四川大学学报. 自然科学版, 2018
Itis well known that in quantum information quantum relative is monotonically decreasing under the completely positive and trace-preserving maps. For a new proposed sandwiched R\'enyi quantum relative, a map that is linear trace-preserving and whose ...
wang you le, Luo Maokang, DENG Ke
doaj  

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

open access: yesMolecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder   +10 more
wiley   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

open access: yesMolecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy